Tisagenlecleucel (tisa-cel) [205], axicabtagene ciloleucel (axi-cel) [206] and lisocabtagene maraleucel (liso-cel) [207] have shown potent therapeutic efficacy against CD19+ DLBCL cells. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.